When Maria Rodriguez turned 45, her doctor handed her a list of options for colorectal cancer screening—stool tests, blood draws, even at-home kits—but one stood out with a legacy of life-saving precision: colonoscopy. Across the U.S., health providers are now receiving updated guidance from the American Gastroenterological Association (AGA), reaffirming colonoscopy as the gold standard in colorectal cancer screening. With colorectal cancer rates rising in adults under 50, the clarity couldn’t come sooner. The AGA’s message is clear: screening saves lives, but not all tests are created equal.
Colonoscopy remains the only method that both detects cancer early and prevents it outright. During the procedure, doctors can identify and remove precancerous polyps before they develop into tumors—a dual advantage no other screening can match. This capability is why the AGA continues to recommend colonoscopy as the top choice for average-risk adults starting at age 45. For patients like Maria, that means peace of mind backed by decades of evidence.
Stool-based tests, such as the fecal immunochemical test (FIT) or multitarget stool DNA test (Cologuard), are acceptable alternatives when colonoscopy isn’t accessible or feasible. But the AGA stresses a critical caveat: a positive result on any stool test must be followed by a colonoscopy. These tests also require strict adherence to repeat schedules—annually for FIT, every three years for Cologuard—to remain effective. Missed rounds mean missed opportunities for early detection.
Blood-based screening options, meanwhile, are raising red flags among experts. While marketed as convenient, these tests are significantly less effective at catching early-stage cancer and, crucially, cannot detect precancerous polyps at all. "A blood test might tell you something is wrong, but it can’t stop cancer before it starts," says Dr. Anjana Bhadkamkar, AGA panelist and gastroenterologist at Emory University. "That’s a dangerous gap when prevention is within reach."
The AGA’s updated clinical guidance, published to inform both patients and primary care providers, underscores a growing need for informed decision-making. With rising incidence rates—especially among younger adults—choosing the right screening method isn’t just a medical decision; it’s a matter of long-term survival. As new technologies emerge, the message remains grounded in evidence: the best test is the one that works, and for now, colonoscopy still leads the field. For millions approaching midlife, the path to prevention may begin not with a vial or a kit, but with a single, powerful procedure that does both.